48 results on '"Vangrevelinghe, Eric"'
Search Results
2. Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors
3. Identification and characterization of a phenyl-thiazolyl-benzoic acid derivative as a novel RAR/RXR agonist
4. Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood
5. Supplementary Table S2 from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
6. Data from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
7. Supplementary Figures, Methods, and References from Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
8. Supplementary Data from Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
9. Novel Concept for Super-Soft Topical Drugs: Deactivation by an Enzyme-Induced Switch into an Inactive Conformation.
10. Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an In Vivo Efficacious TLR7/8 Antagonist
11. Conformational Studies of Poly(Methylidene Malonate 2.1.2)
12. Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay
13. Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain
14. Indolyl-naphthyl-maleimides as potent and selective inhibitors of protein kinase C-α/β
15. NIBR-LTSi is a selective LATS kinase inhibitor activating YAP signaling and expanding tissue stem cells in vitroand in vivo
16. Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model
17. An Activating Janus Kinase-3 Mutation Is Associated with Cytotoxic T Lymphocyte Antigen-4-Dependent Immune Dysregulation Syndrome
18. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model
19. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension
20. Syk inhibitors with high potency in presence of blood
21. An Integrated Approach for Fragment‐Based Lead Discovery: Virtual, NMR, and High‐Throughput Screening Combined with Structure‐Guided Design. Application to the Aspartyl Protease Renin.
22. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
23. Discovery and Profiling of a Selective and Efficacious Syk Inhibitor
24. Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)
25. 2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes
26. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors
27. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors
28. JAK2 L884P Mutation Confers Resistance To The Type II JAK2 Inhibitor NVP-BBT594 When Co-Occurring With JAK2 R683G But Not JAK2 V617F
29. A Novel Class of Oral Direct Renin Inhibitors: Highly Potent 3,5-Disubstituted Piperidines Bearing a Tricyclic P3–P1 Pharmacophore
30. Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
31. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
32. Genetic Resistance to JAK2 Enzymatic Inhibitors Is Overcome by HSP90 Inhibition
33. Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family
34. Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805
35. Novel, Potent and Selective JAK2 Inhibitors.
36. A Small-Molecule Dengue Virus Entry Inhibitor
37. Computational Approaches for Fragment Optimization
38. Discovery and Profiling ofa Selective and EfficaciousSyk Inhibitor.
39. New Developments and Applications of Docking and High-Throughput Docking for Drug Design and in silico Screening
40. Synthesis and Wagner—Meerwein Rearrangement of 9-(α-Hydroxyalkyl)xanthenes to 10-Substituted Dibenz[b,f]oxepins: Scope, Limitations and ab initio Calculations.
41. Synthesis and Wagner-Meerwein Rearrangement of 9-(α-Hydroxyalkyl)xanthenes to 10-Substituted Dibenz[b,f]oxepins: Scope, Limitations and ab initio Calculations
42. Discovery of a Potent and Selective Protein Kinase CK2 Inhibitor by High-Throughput Docking
43. Structure-Based Design and Synthesis of 2-Benzylidene-benzofuran-3-ones as Flavopiridol Mimics
44. 3D-QSAR CoMFA Study on Imidazolinergic I2 Ligands: A Significant Model through a Combined Exploration of Structural Diversity and Methodology
45. Molecular modelling of poly(methylidene malonate 2.1.2) using a continuum solvation approach
46. A NovelClass of Oral Direct Renin Inhibitors: HighlyPotent 3,5-Disubstituted Piperidines Bearing a Tricyclic P3–P1Pharmacophore.
47. Type II JAK2 Inhibitor NVP-CHZ868 Is Active in VivoAgainst JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)
48. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.